Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Sanofi SA — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.49, while Sanofi SA trades at $42.96 (market cap $103.41B). The key difference: Sanofi SA pays a 5.65% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SGOV | SNY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $100.72 | $52.34 |
52-Week Low | $100.28 | $41.33 |
Market Cap | — | $103.41B |
Enterprise Value | — | $123.44B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV trades at $100.475 with minimal daily movement, showing price stability amid bearish technical signals. The stock faces selling pressure with moving averages indicating downward momentum, while oscillators remain neutral. Recent dividend activity shows consistent payouts, though key financial ratios remain unavailable for fundamental assessment.
The outlook remains cautious given the bearish technical setup and lack of fundamental data visibility. Investment opportunities appear limited without clear earnings metrics, while risks include continued technical weakness and market volatility affecting price stability. Investors require updated financial disclosures for proper valuation assessment.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
